|
|
|
|
|
|
|
|
|
<TABLE> <S> <C>
<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS CONTAINED IN THE COMPANY'S QUARTERLY
REPORT ON FORM 10-Q FOR THE QUARTER ENDED JUNE 30, 2000 AND IS QUALIFIED IN ITS
ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000,000
<S> <C>
<PERIOD-TYPE> 6-MOS
<FISCAL-YEAR-END> DEC-31-2000
<PERIOD-START> JAN-01-2000
<PERIOD-END> JUN-30-2000
<CASH> 136
<SECURITIES> 1,485
<RECEIVABLES> 333
<ALLOWANCES> 21
<INVENTORY> 273
<CURRENT-ASSETS> 2,383
<PP&E> 2,494
<DEPRECIATION> 855
<TOTAL-ASSETS> 4,543
<CURRENT-LIABILITIES> 836
<BONDS> 223
0
0
<COMMON> 0
<OTHER-SE> 3,484
<TOTAL-LIABILITY-AND-EQUITY> 4,543
<SALES> 1,504
<TOTAL-REVENUES> 1,729
<CGS> 187
<TOTAL-COSTS> 187
<OTHER-EXPENSES> 393<F1>
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 8
<INCOME-PRETAX> 824
<INCOME-TAX> 256
<INCOME-CONTINUING> 569
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 569
<EPS-BASIC> 0.55
<EPS-DILUTED> 0.52
<FN>
<F1>Item consists of research and development expenses.
</FN>
</TABLE>
|
|